DOCSLIB.ORG

Aldrich Raman

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'- 13183 (+)-B- BINAPHTHYL)PALLADIUM(II) CH METHOXYDIISOPINOCAMPHEYLB 10290 ((R)-(+)-3-HYDROXY-2- ORANE METHYLPROPYL)- 9005 (+)-BICUCULLINE, 98% TRIPHENYLPHOSPHONIUM 9410 (+)-BIOTIN 4-NITROPHENYL BROMIDE, 97% ESTER, 99% 10291 ((S)-(-)-3-HYDROXY-2- 4325 (+)-BIOTIN, 99% METHYLPROPYL)- 6982 (+)-BOLDINE HYDROCHLORIDE, TRIPHENYLPHOSPHONIUM 99% BROMIDE, 97% 236 (+)-CAMPHENE, TECH., 80% 6158 (+)-(4,6-O-BENZYLIDENE)METHYL- 8634 (+)-CARBOBENZYLOXY-D- ALPHA-D- GLUCOPYRANOSIDE, PROLINE, 98% 97% 6294 (+)-CATECHIN HYDRATE, 98% 13483 (+)-(S)-N,N-DIMETHYL-1-((R)-1',2- 11867 (+)-CINCHONINE, 85% BIS(DI- 753 (+)-CIS-P-MENTHANE-3,8-DIOL, PHENYLPHOSPHINO)FERROCENY 97% L)E 11734 (+)-CYTIDINE-5'- 1258 (+)-1,4-DIOXASPIRO(4.5)DECANE-2- MONOPHOSPHORIC ACID METHANOL, 98% MONOHYDRATE, 99% 12571 (+)-11ALPHA- 12557 (+)-DEHYDROISOANDROSTERONE, HYDROXYPROGESTERONE, 95% 97% 11630 (+)-2'-DEOXYURIDINE, 99+% 13433 (+)-DI-MU-CHLOROBIS(2-(1- 6153 (+)-2,3-O-BENZYLIDENE-D- (DIMETHYLAMINO)- THREITOL, 99% ETHYL)PHENYL-C,N)DIPALLADIU 10256 (+)-2,3-O-ISOPROPYLIDENE-2,3- 3845 (+)-DIACETYL-L-TARTARIC DIHYDROXY- 1,4- ANHYDRIDE, 97% BIS(DIPHENYLPHOSPHINO)BUT 12640 (+)-DIGITOXIGENIN, 98% 1260 (+)-2,3-O-ISOPROPYLIDENE-L- 12644 (+)-DIGOXIN, 97% THREITOL, 99% 2246 (+)-DIHYDROCARVONE, 98%, 12975 (+)-3',5'-O-(1,1,3,3- MIXTURE OF ISOMERS TETRAISOPROPYL-1,3- 12543 (+)-DIHYDROCHOLESTEROL, 96% DISILOXANEDIYL)CYTIDINE, 97% 8742 (+)-DIMETHYL 2,3-O- 8581 (+)-3,3',5-TRIIODO-L-THYRONINE, BENZYLIDENE-D- TARTRATE, 99% SODIUM SALT, 97% 3617 (+)-DIMETHYL 2,3-O- 2282 (+)-3- ISOPROPYLIDENE-D TARTRATE, (TRIFLUOROACETYL)CAMPHOR, 98% 98% 12675 (+)-EMETINE DIHYDROCHLORIDE HYDRATE, 97% 3757 (+)-GIBBERELLIC ACID, 90+% 9003 (+)-GRISEOFULVIN (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 1 of 211 Aldrich Raman Index Compound Name Index Compound Name 1192 (+)-LIMONENE OXIDE, 97%, 402 (+/-)-1,2- MIXTURE OF CIS AND TRANS DIBROMOHEXAFLUOROPROPANE, 237 (+)-LONGIFOLENE, 98+% 95% 3932 (+)-MENTHYL CHLOROFORMATE 352 (+/-)-1,2-DIBROMOPROPANE, 97% 4023 (+)-N,N'- 1028 (+/-)-1,2-DICHLOROETHYL ETHYL DIALLYLTARTARDIAMIDE, 99+% ETHER, TECH., 90% 9216 (+)-N,N'-DIBENZYL-L- 1435 (+/-)-1,2-DIMETHYLPROPYLAMINE, TARTRAMIDE, 99% 98+% 4040 (+)-N-ACETYLMURAMIC ACID, 6003 (+/-)-1,2-DIPHENYL-2-PROPANOL, 97% 98% 10221 (+)- 639 (+/-)-1,2-DODECANEDIOL, 90% NEOMENTHYLDIPHENYLPHOSPHI 5702 (+/-)-1,2-EPOXY-3- NE, TECH. 85% PHENOXYPROPANE, 99% 1240 (+)-NOE-LACTOL DIMER, 99+% 627 (+/-)-1,2-HEXANEDIOL, 98% 3097 (+)-OCTOPINE, 98% 1176 (+/-)-1,3-BUTADIENE DIEPOXIDE, 6940 (+)-P-BROMOTETRAMISOLE 97% OXALATE, 99% 606 (+/-)-1,3-BUTANEDIOL, 99% 792 (+)-P-MENTH-1-EN-9-OL, 97%, 2735 (+/-)-1,3- MIXTURE OF ISOMERS CYCLOHEXANEDICARBOXYLIC 4033 (+)-PANTOTHENIC ACID, CALCIUM ACID, 98%, MIXTURE OF CIS AND SALT HYDRATE, 98% TRANS 4032 (+)-PANTOTHENIC ACID, SODIUM 1453 (+/-)-1,3-DIAMINOPENTANE, 98% SALT, 98% 356 (+/-)-1,3-DIBROMOBUTANE, 98% 10660 (+)-PILOCARPINE 847 (+/-)-1,4-DIBROMO-2,3- HYDROCHLORIDE, 99% BUTANEDIOL, 95% 6155 (+)-TRANS-A,A'-(2,2-DIMETHYL- 6903 (+/-)-1-(1- 1,3-DIOXOLANE-4,5- NAPHTHYL)ETHYLAMINE, 98% DIYL)BIS(DIPHENYLMETHA 5753 (+/-)-1-(4-BROMOPHENOXY)-1- 6995 (+)-TROGER'S BASE, ETHOXYETHANE, TECH., 94% FLUKABRAND CHIRA- SELECT 6083 (+/-)-1-(4- REAGENT, 99+% CHLOROPHENYL)ETHANOL, 98% 7663 (+)-USNIC ACID, 98% 8716 (+/-)-1-ACETOXY-8-HYDROXY- 12553 (+)-VITAMIN D/3, CRYSTALLINE, 1,4,4A,9A- 99+% TETRAHYDROANTHRAQUINONE, 5242 (+/-)-(1,2- 98% DIBROMOETHYL)BENZENE, 99% 4936 (+/-)-1-AMINOETHYLPHOSPHONIC 4940 (+/-)-(1- ACID, 96% AMINOBUTYL)PHOSPHONIC ACID, 8061 (+/-)-1- 98% BENZOCYCLOBUTENECARBOXYL 5695 (+/-)-(2,3-EPOXYPROPYL)BENZENE, IC ACID, 99% 98% 359 (+/-)-1-BROMO-3-CHLORO-2- 808 (+/-)-(2-ENDO,3-EXO)- METHYLPROPANE, 99% BICYCLO(2.2.2)OCT-5- ENE-2,3- 722 (+/-)-1-CYCLOHEXYLETHANOL, DIMETHANOL, 96% 97% 5954 (+/-)-1,1'-BI-2-NAPHTHOL, 99% 4814 (+/-)-1-HYDROXY-2,5-DIOXO-3- 10383 (+/-)-1,1'-BINAPHTHYL-2,2'-DIYL PYRROLIDINE- SULFONIC ACID, HYDROGEN PHOSPHATE, 95% NA SALT HYDRA 3920 (+/-)-1,2,2,2-TETRACHLOROETHYL 1175 (+/-)-1-METHOXY-2- CHLORO- FORMATE, 98% METHYLPROPYLENE OXIDE, 97% 388 (+/-)-1,2,3,4- 1060 (+/-)-1-METHOXY-2-PROPANOL, TETRACHLOROBUTANE, 97% 98% 8058 (+/-)-1,2,3,4-TETRAHYDRO-3- 2722 (+/-)-1-METHYL-2-CYCLOHEXENE- ISOQUINOLINE- CARBOXYLIC 1-CARBOXYLIC ACID, 99% ACID HYDROCHLORID 6214 (+/-)-1-PHENYL-1,2-ETHANEDIOL, 860 (+/-)-1,2,3-TRIHYDROXYHEXANE, 97% 99% 6007 (+/-)-1-PHENYL-1-PROPANOL, 99% 608 (+/-)-1,2-BUTANEDIOL, 99% 6195 (+/-)-1-PHENYL-2-PENTANOL, 99% 364 (+/-)-1,2-DIBROMO-3,3- 8697 (+/-)-1-PHENYLETHYL DIMETHYLBUTANE, 97% PROPIONATE, 98% (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 2 of 211 Aldrich Raman Index Compound Name Index Compound Name 4801 (+/-)-10-CAMPHORSULFONIC ACID, 3992 (+/-)-2-CHLOROPROPIONAMIDE, SODIUM SALT, 97% 98% 4842 (+/-)-10-CAMPHORSULFONYL 4543 (+/-)-2-CHLOROPROPIONITRILE, CHLORIDE, 98% 97% 6011 (+/-)-2,2-DIMETHYL-1-PHENYL-1- 2725 (+/-)-2-CIS,4-TRANS-ABSCISIC PROPANOL, 99% ACID, 98%, SYNTHETIC 846 (+/-)-2,3-DIBROMO-1,4- 1645 (+/-)-2- BUTANEDIOL, 99% DIMETHYLAMINOISOPROPYL 4546 (+/-)-2,3-DIBROMOPROPIONITRILE, CHLORIDE HYDROCHLORIDE, 98% TECH., 90% 1211 (+/-)-2- 6104 (+/-)-2,4-DICHLORO-ALPHA- ETHOXYTETRAHYDROFURAN, METHYLBENZYL ALCOHOL, 96% 99% 2168 (+/-)-2,4- 2477 (+/-)-2-ETHYLHEXANOIC ACID, DIMETHYLCYCLOPENTANONE, 99% 95%, MIXTURE OF CIS AND TRANS 3929 (+/-)-2-ETHYLHEXYL 3096 (+/-)-2,6-DIAMINOPIMELIC ACID, CHLOROFORMATE, 99% 98% 1442 (+/-)-2-ETHYLHEXYLAMINE, 98% 8067 (+/-)-2-(2- 558 (+/-)-2-HEPTANOL, 96% CHLOROPHENOXY)PROPIONIC 2616 (+/-)-2-HYDROXY-3- ACID, 98% METHYLBUTYRIC ACID, 99% 8082 (+/-)-2-(3- 2858 (+/-)-2-HYDROXYBUTYRIC ACID, CHLOROPHENOXY)PROPIONIC SODIUM SALT, 97% ACID, 98% 2620 (+/-)-2-HYDROXYCAPROIC ACID, 8128 (+/-)-2-(4- 99% CHLOROPHENOXY)PROPIONIC 2618 (+/-)-2-HYDROXYISOCAPROIC ACID, 98+% ACID, 99% 1931 (+/-)-2-(AMINOMETHYL)-15- 2863 (+/-)-2-HYDROXYVALERIC ACID, CROWN-5, 97% SODIUM SALT HYDRATE, 98% 1932 (+/-)-2-(AMINOMETHYL)-18- 6194 (+/-)-2-METHOXY-2- CROWN-6, 95% PHENYLETHANOL, 99% 1701 (+/-)-2-AMINO-1-BUTANOL, 97% 6046 (+/-)-2-METHOXY-ALPHA- 1653 (+/-)-2-AMINO-1- METHYLBENZYL ALCOHOL, 97% METHOXYPROPANE, 95% 1229 (+/-)-2- 1707 (+/-)-2-AMINO-3-METHYL-1- METHOXYTETRAHYDROPYRAN, BUTANOL, 97% 98% 1613 (+/-)-2-AMINONORBORNANE 2702 (+/-)-2-METHYL-1- HYDROCHLORIDE, 99% CYCLOHEXANECARBOXYLIC 7616 (+/-)-2-BENZYL-2- ACID, 99%, MIXTURE OF CIS AND (DIMETHYLAMINO)-4'- 7433 (+/-)-2-METHYL-1-INDANONE, 99% MORPHOLINOBUTYROPHENONE, 2468 (+/-)-2-METHYLBUTYRIC ACID, 97% 98% 1136 (+/-)-2-BROMO-1,1,3- 4508 (+/-)-2-METHYLGLUTARONITRILE, TRIMETHOXYPROPANE, 95% TECH., 80% 2583 (+/-)-2-BROMO-3-METHYLBUTYRIC 2473 (+/-)-2-METHYLVALERIC ACID, ACID, 97% 98% 2587 (+/-)-2-BROMOHEXANOIC ACID, 765 (+/-)-2-NORBORNANEMETHANOL, 97% 97%, MIXTURE OF ENDO AND EXO 2590 (+/-)-2-BROMOOCTANOIC ACID, 8028 (+/-)-2-PHENOXYPROPIONIC ACID, 97% 98+% 297 (+/-)-2-BROMOPENTANE, 95% 6014 (+/-)-2-PHENYL-1,2-PROPANEDIOL, 3993 (+/-)-2-BROMOPROPIONAMIDE, 97% 99% 6206 (+/-)-2-PHENYL-2-BUTANOL, 99% 3875 (+/-)-2-BROMOPROPIONYL 9613 (+/-)-2-PHENYLBUTYRONITRILE, CHLORIDE, TECH. 95% 547 (+/-)-2-BUTANOL, 99% 7431 (+/-)-2-PHENYLBUTYROPHENONE, 9089 (+/-)-2-CHLORO-2-PHENYLACETYL 98% CHLORIDE, TECH., 90% 7377 (+/-)-2- 851 (+/-)-2-CHLOROCYCLOHEXANOL, PHENYLCYCLOHEPTANONE, 99% TECH., 90% 8555 (+/-)-2-PHENYLGLYCINE, 95% (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 3 of 211 Aldrich Raman Index Compound Name Index Compound Name 5752 (+/-)-2- 2909 (+/-)-3-METHYL-2-OXOPENTANOIC PHENYLPROPIONALDEHYDE ACID, SODIUM SALT, 98+% DIMETHYL ACETAL, 99% 4208 (+/-)-3-METHYL-2- 1832 (+/-)-2-PIPERIDINEMETHANOL, 97% PYRROLIDINONE, 98% 4219 (+/-)-2-PYRROLIDONE-5- 2174 (+/-)-3-METHYLCYCLOHEXANONE, CARBOXYLIC ACID, 99% 97% 568 (+/-)-2-UNDECANOL, 97% 712 (+/-)-3-METHYLCYCLOPENTANOL, 1858 (+/-)-3,3,5- 99%, MIXTURE OF ISOMERS TRIMETHYLHEXAHYDROAZEPINE 2165 (+/-)-3- , 98%, MIXTURE OF ISOMERS METHYLCYCLOPENTANONE, 99% 573 (+/-)-3,3-DIMETHYL-2-BUTANOL, 1225 (+/-)-3- 98% METHYLTETRAHYDROPYRAN, 12180 (+/-)-3,5-DIMETHYL-1-HEXYN-3-OL, 98% 99% 7817 (+/-)-3-PHENYLBUTYRALDEHYDE,
Recommended publications
  • Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
  • Inhaled Nitric Oxide Therapy in Adults Benedict C Creagh-Brown, Mark JD Griffiths and Timothy W Evans

    Inhaled Nitric Oxide Therapy in Adults Benedict C Creagh-Brown, Mark JD Griffiths and Timothy W Evans

    Available online http://ccforum.com/content/13/3/212 Review Bench-to-bedside review: Inhaled nitric oxide therapy in adults Benedict C Creagh-Brown, Mark JD Griffiths and Timothy W Evans Unit of Critical Care, Faculty of Medicine, Imperial College, London, UK and Adult Intensive Care Unit, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK Corresponding author: Timothy W Evans, [email protected] Published: 29 May 2009 Critical Care 2009, 13:212 (doi:10.1186/cc7734) This article is online at http://ccforum.com/content/13/3/221 © 2009 BioMed Central Ltd Abstract Administration of inhaled nitric oxide to adults Nitric oxide (NO) is an endogenous mediator of vascular tone and The licensed indication of iNO is restricted to persistent host defence. Inhaled nitric oxide (iNO) results in preferential pulmonary hypertension in neonates, yet most iNO is pulmonary vasodilatation and lowers pulmonary vascular resis- administered for unlicensed indications. Pharmaceutical iNO tance. The route of administration delivers NO selectively to is available at a very high cost, and in light of this and ventilated lung units so that its effect augments that of hypoxic concerns over potential adverse effects of iNO, international pulmonary vasoconstriction and improves oxygenation. This guidelines have been developed. An advisory board under the ‘Bench-to-bedside’ review focuses on the mechanisms of action of iNO and its clinical applications, with emphasis on acute lung injury auspices of the European Society of Intensive Care Medicine and the acute respiratory distress syndrome. Developments in our and the European Association of Cardiothoracic Anaes- understanding of the cellular and molecular actions of NO may thesiologists published its recommendations in 2005 [1].
  • Aldrich Vapor

    Aldrich Vapor

    Aldrich Vapor Library Listing – 6,611 spectra This library is an ideal tool for investigator using FT-IR to analyze gas phase materials. It contains gas phase spectra collected by Aldrich using a GC-IR interface to ensure chromatographically pure samples. The Aldrich FT-IR Vapor Phase Library contains 6,611 gas phase FT-IR spectra collected by Aldrich Chemical Company using a GC interface. The library includes compound name, molecular formula, CAS (Chemical Abstract Service) registry number, Aldrich catalog number, and page number in the Aldrich Library of FT-IR Spectra, Edition 1, Volume 3, Vapor-Phase. Aldrich Vapor Index Compound Name Index Compound Name 6417 ((1- 3495 (1,2-Dibromoethyl)benzene; Styrene Ethoxycyclopropyl)oxy)trimethylsilane dibromide 2081 (+)-3-(Heptafluorobutyryl)camphor 3494 (1-Bromoethyl)benzene; 1-Phenylethyl 2080 (+)-3-(Trifluoroacetyl)camphor bromide 262 (+)-Camphene; 2,2-Dimethyl-3- 6410 (1-Hydroxyallyl)trimethylsilane methylenebicyclo[2.2.1]heptane 6605 (1-Methyl-2,4-cyclopentadien-1- 2828 (+)-Diisopropyl L-tartrate yl)manganese tricarbonyl 947 (+)-Isomenthol; [1S-(1a,2b,5b)]-2- 6250 (1-Propynyl)benzene; 1-Phenylpropyne Isopropyl-5-methylcyclohexano 2079 (1R)-(+)-3-Bromocamphor, endo- 1230 (+)-Limonene oxide, cis + trans; (+)-1,2- 2077 (1R)-(+)-Camphor; (1R)-(+)-1,7,7- Epoxy-4-isopropenyl-1- Trimethylbicyclo[2.2.1]heptan- 317 (+)-Longifolene; (1S)-8-Methylene- 976 (1R)-(+)-Fenchyl alcohol, endo- 3,3,7-trimethyltricyclo[5.4.0 2074 (1R)-(+)-Nopinone; (1R)-(+)-6,6- 949 (+)-Menthol; [1S-(1a,2b,5a)]-(+)-2- Dimethylbicyclo[3.1.1]heptan-2-
  • Dynamic Regulation of Synaptic GABA Release by the Glutamate-Glutamine Cycle in Hippocampal Area CA1

    Dynamic Regulation of Synaptic GABA Release by the Glutamate-Glutamine Cycle in Hippocampal Area CA1

    The Journal of Neuroscience, August 16, 2006 • 26(33):8537–8548 • 8537 Development/Plasticity/Repair Dynamic Regulation of Synaptic GABA Release by the Glutamate-Glutamine Cycle in Hippocampal Area CA1 Shu-Ling Liang,1 Gregory C. Carlson,1 and Douglas A. Coulter1,2 1Division of Neurology and the Pediatric Regional Epilepsy Program, Children’s Hospital of Philadelphia, and 2Departments of Pediatrics, Neurology, and Neuroscience, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 Vesicular GABA and intraterminal glutamate concentrations are in equilibrium, suggesting inhibitory efficacy may depend on glutamate availability. Two main intraterminal glutamate sources are uptake by neuronal glutamate transporters and glutamine synthesized through the astrocytic glutamate-glutamine cycle. We examined the involvement of the glutamate-glutamine cycle in modulating GABAergic synaptic efficacy. In the absence of neuronal activity, disruption of the glutamate-glutamine cycle by blockade of neuronal glutamine transport with ␣-(methylamino) isobutyric acid (MeAIB; 5 mM) or inhibition of glutamine synthesis in astrocytes with methionine sulfoximine (MSO; 1.5 mM) had no effect on miniature IPSCs recorded in hippocampal area CA1 pyramidal neurons. How- ever, after a period of moderate synaptic activity, application of MeAIB, MSO, or dihydrokainate (250 ␮M; an astrocytic glutamate transporter inhibitor) significantly reduced evoked IPSC (eIPSC) amplitudes. The MSO effect could be reversed by exogenous application of glutamine (5 mM), whereas glutamine could not rescue the eIPSC decreases induced by the neuronal glutamine transporter inhibitor MeAIB. The activity-dependent reduction in eIPSCs by glutamate-glutamine cycle blockers was accompanied by an enhanced blocking effect of the low-affinity GABAA receptor antagonist, TPMPA [1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid], consistent with diminished GABA release.
  • Methionine Sulfoximine: a Novel Anti Inflammatory Agent

    Methionine Sulfoximine: a Novel Anti Inflammatory Agent

    Wayne State University Wayne State University Dissertations January 2018 Methionine Sulfoximine: A Novel Anti Inflammatory Agent Tyler Peters Wayne State University, [email protected] Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Biochemistry Commons Recommended Citation Peters, Tyler, "Methionine Sulfoximine: A Novel Anti Inflammatory Agent" (2018). Wayne State University Dissertations. 2124. https://digitalcommons.wayne.edu/oa_dissertations/2124 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. METHIONINE SULFOXIMINE: A NOVEL ANTI-INFLAMMATORY AGENT by TYLER J. PETERS DISSERTATION Submitted to the Graduate School of Wayne State University – School of Medicine Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOHPY 2018 MAJOR: BIOCHEMISTRY & MOL. BIOLOGY Approved By: __________________________________________ Advisor Date DEDICATION This work is dedicated to my family. I wouldn’t have made it this far without your unconditional love and support. ii ACKNOWLEDGEMENTS Thank you Dr. Brusilow, I consider myself very fortunate for having the privilege of working in the laboratory of Dr. William S.A. Brusilow these past few years. Under his mentorship, my scientific autonomy was always respected, and my opinions were always valued with consideration. I am thankful for his guidance and support as an advisor; I truly admire his patience and envy his calm demeanor. He exemplifies scientific integrity, and his dedication to develop MSO has inspired me. I had never experienced consistent failure in any aspect of life before encountering scientific research; at times I felt that Dr.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Glutamate and GABA Dynamics in Early Ischaemia of Rat

    Glutamate and GABA Dynamics in Early Ischaemia of Rat

    J. Physiol. (2002). 543.P Research Symposium – Mechanisms of Ischaemic Cell Death 25S ATP occurring in ischaemia may prevent a protective uptake of glutamate into glia in early ischaemia: with glutamine synthetase Glutamate and GABA dynamics in early ischaemia of rat inhibited, uptake of only a little glutamate released from neurons hippocampal slices may be sufficient to raise [glutamate]i in glia sufficiently to D. Attwell, N.J. Allen, M. Hamman and D.J. Rossi inhibit further uptake. Department of Physiology, University College London, Gower Street, Hamann, M. et al. (2002). Eur. J. Neurosci. 15, 308–314. London WC1E 6BT, UK Rossi, D.J. et al. (2000). Nature 403, 316–321. During brain ischaemia, the run-down of transmembrane ion gradients caused by the fall of ATP levels occurring leads to a rise This work was supported by The Wellcome Trust. in extracellular glutamate and GABA concentrations. The rise of glutamate concentration triggers neuronal death. In simulated All procedures accord with current local guidelines. ischaemia of hippocampal slices, taken from rats humanely killed in accordance with UK animal use legislation, we have used receptors in whole-cell patch-clamped CA1 pyramidal cells to sense released glutamate and GABA. ECl was set to 0 mV, so that currents mediated by ionotropic GABA receptors were inward, Cation channels: a radical way of killing cells and membrane current was recorded at _30 mV to allow glutamate sensing by NMDA and AMPA receptors. Mike Ashford On applying superfusion solution mimicking the energy University of Dundee deprivation occurring during severe ischaemia (no oxygen and glucose, cyanide and iodoacetate present), a slow small increase of inward current occurred over the first few minutes, followed by a sudden massive inward current (nanoamps) which then sagged back to a less inward plateau (Rossi et al.
  • Effect of Rutin on Gentamicin-Induced Ototoxicity in Rats: a Biochemical and Histopathological Examination

    Effect of Rutin on Gentamicin-Induced Ototoxicity in Rats: a Biochemical and Histopathological Examination

    ORIGINAL ARTICLE ENT UPDATES 11(1):8-13 DOI: 10.5152/entupdates.2021.887158 Effect of Rutin on Gentamicin-Induced Ototoxicity in Rats: A Biochemical and Histopathological Examination Abstract Objective: Gentamicin is a broad-spectrum aminoglycoside antibiotic administered parenterally for moderate to severe gram-negative infections. Ototoxicity is an im- portant side effect that limits gentamicin use. The aim of this study is to investigate the effect of rutin on gentamicin-induced ototoxicity in rats biochemically and histo- pathologically. Methods: Distilled water was administered by oral gavage to healthy controls (HG) and cobalt administered group (GC). 50 mg/kg rutin was administered by oral gavage to rutin + gentamicin (RGG) group. After one hour, 100 mg/kg gentamicin was injected intraperitoneally (i.p) to the RGG and GC animal groups. This procedure was repeated once a day for 14 days. Results: Malondialdehyde (MDA), nuclear factor-κB(NF-κB), tumor necrosis factor alpha (TNF-α) and interleukin-1 beta(IL-1β) levels in the cochlear nerve tissue of gen- tamicin-treated animals were significantly higher compared to healthy controls and rutin + gentamicin treated rats. On the other hand, the amount of total Glutathione (tGSH) was significantly lower compared to the control and rutin group. Histopatho- logical examination revealed degenerated myelinated nerve fibers in the gentamicin group and Schwann cell nuclei were generally not seen. There was a high accumula- tion of collagen fiber in the tissue and dilated blood capillaries. In the rutin group, my- elinated nerve fibers mostly exhibited normal morphology, Schwann cell nuclei were İsmail Salcan1 evident and the vessels were normal.
  • 1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC

    1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC

    1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5-
  • C-Metalated Nitriles: Diastereoselective Alkylations and Arylations

    C-Metalated Nitriles: Diastereoselective Alkylations and Arylations

    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 12-20-2019 C-Metalated Nitriles: Diastereoselective Alkylations and Arylations Robert John Mycka Duquesne University Follow this and additional works at: https://dsc.duq.edu/etd Part of the Organic Chemistry Commons Recommended Citation Mycka, R. J. (2019). C-Metalated Nitriles: Diastereoselective Alkylations and Arylations (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1851 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. C-METALATED NITRILES: DIASTEREOSELECTIVE ALKYLATIONS AND ARYLATIONS A Dissertation Submitted to the Bayer School of Natural and Environmental Sciences Duquesne University In partial fulfillment of the requirements for the degree of Doctor of Philosophy By Robert J. Mycka December 2019 Copyright by Robert J. Mycka 2019 C-METALATED NITRILES: DIASTEREOSELECTIVE ALKYLATIONS AND ARYLATIONS By Robert J. Mycka Approved November 13, 2019 ________________________________ ________________________________ Dr. Bruce D. Beaver Dr. Jeffrey D. Evanseck Professor of Chemistry and Biochemistry Professor of Chemistry and Biochemistry (Committee Chair) (Committee Member) ________________________________ ________________________________ Dr. Shahed U. M. Khan Dr. Patrick T. Flaherty Associate Professor of Chemistry and
  • An Overview on “Stages of Anesthesia and Some Novel General Anesthetics Drug”

    An Overview on “Stages of Anesthesia and Some Novel General Anesthetics Drug”

    Rohit Jaysing Bhor. et al. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 5(4), 2017, 132-140. Review Article ISSN: 2349 – 7106 Asian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page: www.ajrcps.com AN OVERVIEW ON “STAGES OF ANESTHESIA AND SOME NOVEL GENERAL ANESTHETICS DRUG” Rohit Jaysing Bhor *1 , Bhadange Shubhangi 1, C. J. Bhangale 1 1* Department of Pharmaceutical Chemistry, PRES’s College of Pharmacy Chincholi, Tal-Sinner, Dist-Nasik, Maharashtra, India. ABSTRACT Anesthesia is a painless performance of medical producers. There are both major and minor risks of anesthesia. Anesthesia is a state of temporary induced loss of sensation or awareness. It gives analgesia i.e. relief from pain or prevention of pain and paralysis. General anaesthesia is a medically induced state of unconsciousness. It gives loss of protective reflux. It is carried out to allow medical procedures or medical surgery. It can be classified into 3 types like Intravenous Anesthetics Drug; Miscellaneous Drug; and Inhalational anesthetic Drug. Sodium thiopental is an ultra-short-acting barbiturate and has been used commonly in the induction phase of anesthesia. Methohexital is an example of barbiturates derivatives. It is classified as short-acting, and has a rapid onset of action. KEYWORDS Anesthesia, Sodium thiopental, Methohexital and Propofol. Author for Correspondence: INTRODUCTON Anesthesia is a state of temporary induced loss of sensation or awareness. It gives analgesia i.e. relief 1 Rohit Jaysing Bhor, from pain or prevention of pain and paralysis . A patient under the effects of anesthetic drug is known Department of Pharmaceutical Chemistry, as anesthetized.